Answers are grounded in this paper and cite their sources.
Tumour biorepositories are essential in identifying tumour molecular subtypes and biomarkers. Most tumour biorepositories include tissues from cancer patients in clinical studies and/or hospitals with which investigators are affiliated. Inherent limitations of such repositories include risk of selection bias due to convenience sampling (e.g., selection towards more advanced and more heavily treated cancer patients at tertiary care centres), lack of (or recall bias) in long-term pre-diagnostic exposure information, and inability to calculate the incidence rates of both overall cancer and tumour subtypes.
No takes yet. Share an insight, caveat, or question.
Ugai et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: